HomeCompareGRPH vs SBUX

GRPH vs SBUX: Dividend Comparison 2026

GRPH yields 64.78% · SBUX yields 2.84%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GRPH wins by $654.3K in total portfolio value
10 years
GRPH
GRPH
● Live price
64.78%
Share price
$3.18
Annual div
$2.06
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$821.3K
Annual income
$203,467.89
Full GRPH calculator →
SBUX
SBUX
● Live price
2.84%
Share price
$86.72
Annual div
$2.46
5Y div CAGR
48.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$167.0K
Annual income
$71,136.45
Full SBUX calculator →

Portfolio growth — GRPH vs SBUX

📍 GRPH pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodGRPHSBUX
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, GRPH + SBUX cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
GRPH pays
SBUX pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GRPH
Annual income on $10K today (after 15% tax)
$5,506.29/yr
After 10yr DRIP, annual income (after tax)
$172,947.71/yr
SBUX
Annual income on $10K today (after 15% tax)
$241.12/yr
After 10yr DRIP, annual income (after tax)
$60,465.98/yr
At 15% tax rate, GRPH beats the other by $112,481.72/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GRPH + SBUX for your $10,000?

GRPH: 50%SBUX: 50%
100% SBUX50/50100% GRPH
Portfolio after 10yr
$494.2K
Annual income
$137,302.18/yr
Blended yield
27.78%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on SBUX right now

GRPH
Analyst Ratings
7
Hold
1
Sell
Consensus: Hold
Price Target
$4.00
+25.8% upside vs current
Range: $2.00 — $7.00
Altman Z
5.3
Piotroski
4/9
SBUX
Analyst Ratings
28
Buy
27
Hold
3
Sell
Consensus: Buy
Price Target
$104.00
+19.9% upside vs current
Range: $90.00 — $120.00
Altman Z
2.6
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GRPH buys
0
SBUX buys
0
No recent congressional trades found for GRPH or SBUX in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricGRPHSBUX
Forward yield64.78%2.84%
Annual dividend / share$2.06$2.46
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%48.3%
Portfolio after 10y$821.3K$167.0K
Annual income after 10y$203,467.89$71,136.45
Total dividends collected$690.7K$136.4K
Payment frequencyquarterlyquarterly
SectorStockConsumer Discretionary
Analyst consensusHoldBuy
Analyst price target$4.00$104.00

Year-by-year: GRPH vs SBUX ($10,000, DRIP)

YearGRPH PortfolioGRPH Income/yrSBUX PortfolioSBUX Income/yrGap
1← crossover$17,178$6,477.99$11,121$420.68+$6.1KGRPH
2$28,780$10,399.89$12,548$648.40+$16.2KGRPH
3$47,079$16,284.27$14,440$1,013.98+$32.6KGRPH
4$75,270$24,895.34$17,068$1,617.30+$58.2KGRPH
5$117,738$37,198.68$20,912$2,649.52+$96.8KGRPH
6$180,359$54,379.70$26,875$4,499.29+$153.5KGRPH
7$270,837$77,853.00$36,771$8,014.12+$234.1KGRPH
8$399,056$109,260.19$54,542$15,197.11+$344.5KGRPH
9$577,444$150,453.99$89,602$31,242.49+$487.8KGRPH
10$821,333$203,467.89$167,011$71,136.45+$654.3KGRPH

GRPH vs SBUX: Complete Analysis 2026

GRPHStock

Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. It offers GPH101, a gene-edited autologous hematopoietic stem cell product candidate to directly correct the mutation that causes sickle cell disease and restore normal adult hemoglobin expression; GPH201 for the treatment of X-linked severe combined immunodeficiency syndrome; and GPH301, a product candidate for the treatment of Gaucher disease, a genetic disorder that results in a deficiency in the glucocerebrosidase enzyme. The company was formerly known as Integral Medicines, Inc., and changed its name to Graphite Bio, Inc. in August 2020. Graphite Bio, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

Full GRPH Calculator →

SBUXConsumer Discretionary

Starbucks Corporation, together with its subsidiaries, operates as a roaster, marketer, and retailer of specialty coffee worldwide. The company operates through three segments: North America, International, and Channel Development. Its stores offer coffee and tea beverages, roasted whole beans and ground coffees, single serve products, and ready-to-drink beverages; and various food products, such as pastries, breakfast sandwiches, and lunch items. The company also licenses its trademarks through licensed stores, and grocery and foodservice accounts. The company offers its products under the Starbucks, Teavana, Seattle's Best Coffee, Evolution Fresh, Ethos, Starbucks Reserve, and Princi brands. As of October 3, 2021, it operated 16,826 company-operated and licensed stores in North America; and 17,007 company-operated and licensed stores internationally. The company was founded in 1971 and is based in Seattle, Washington.

Full SBUX Calculator →
📬

Get this GRPH vs SBUX comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GRPH vs SCHDGRPH vs JEPIGRPH vs OGRPH vs KOGRPH vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.